Ken Fisher
LCTX icon

Ken Fisher’s Lineage Cell Therapeutics LCTX Stock Holding History

Ken Fisher’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,000
Closed -$10.9K – 1013
2023
Q4 		$10.9K Buy
+10,000
New +$11K ﹤0.01% 979

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Ken Fisher's LCTX Position: Q1 2024 in Review

Ken Fisher sold out of Lineage Cell Therapeutics (LCTX) in Q1 2024, closing a stake of 10,000 shares — an estimated $10.9K sold.

Ken Fisher first reported a position in LCTX in Q4 2023 and held it in 1 quarter. The position peaked at $10.9K in Q4 2023. 116 funds tracked by Wall St. Rank hold LCTX as of Q1 2024.

  • Ken Fisher reported no remaining Lineage Cell Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Ken Fisher sold 10,000 Lineage Cell Therapeutics shares in Q1 2024, an estimated $10.9K.
  • Ken Fisher first reported a position in Lineage Cell Therapeutics in Q4 2023 and held it in 1 quarter.
  • Ken Fisher's Lineage Cell Therapeutics position peaked at $10.9K in Q4 2023.
  • 116 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2024.

Based on Fisher Asset Management's 13F filing for Q1 2024, filed 9 May 2024.